Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) have been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $17.29.

ALDX has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Thursday, August 10th. Canaccord Genuity reissued a “buy” rating and set a $27.00 target price (up previously from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Cantor Fitzgerald initiated coverage on shares of Aldeyra Therapeutics in a research report on Tuesday, October 24th. They set an “overweight” rating and a $22.00 target price on the stock. Cowen and Company reissued an “outperform” rating and set a $14.00 target price (up previously from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Finally, ValuEngine raised shares of Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 12th.

In related news, major shareholder Life Sciences Maste Perceptive purchased 200,000 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were bought at an average price of $7.25 per share, with a total value of $1,450,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 28.40% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC raised its holdings in shares of Aldeyra Therapeutics by 6.9% in the 3rd quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock worth $22,215,000 after purchasing an additional 200,000 shares during the period. Sphera Funds Management LTD. raised its holdings in Aldeyra Therapeutics by 19.2% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,044,131 shares of the biotechnology company’s stock valued at $7,518,000 after acquiring an additional 168,200 shares during the period. Bank of New York Mellon Corp bought a new stake in Aldeyra Therapeutics during the 3rd quarter valued at $134,000. Virtu KCG Holdings LLC bought a new stake in Aldeyra Therapeutics during the 2nd quarter valued at $104,000. Finally, Vanguard Group Inc. raised its holdings in Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares during the period. 40.06% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics (NASDAQ:ALDX) opened at $6.15 on Monday. Aldeyra Therapeutics has a 1 year low of $3.80 and a 1 year high of $11.90. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. research analysts expect that Aldeyra Therapeutics will post -1.39 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/19/aldeyra-therapeutics-inc-aldx-given-consensus-rating-of-buy-by-analysts.html.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.